Artivion’s Endospan acquisition puts NEXUS at the centre of aortic arch device competition
Artivion now owns NEXUS. The bigger test is whether FDA approval can become a scalable U.S. aortic arch business.
Artivion just bought a bigger aortic future, but investors may not love the waiting game
Artivion’s aortic portfolio is getting stronger, but its 2026 outlook is getting weaker. Can Endospan turn strategy into growth?
NEXUS gets FDA approval: can Endospan finally crack the hardest segment in endovascular aortic repair?
Endospan’s FDA-approved NEXUS system could reshape high-risk aortic arch repair. Read what the approval changes and what clinicians will watch next.